New Zealand markets closed

Spruce Biosciences, Inc. (SPRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.3600+0.0400 (+3.03%)
At close: 04:00PM EDT
1.4900 +0.13 (+9.56%)
After hours: 06:25PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.3200
Open1.3600
Bid1.2500 x 800
Ask1.4900 x 1000
Day's range1.3000 - 1.4000
52-week range1.2500 - 15.0800
Volume51,282
Avg. volume123,311
Market cap31.95M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.8860
Earnings date09 Aug 2022 - 15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.17
  • Business Wire

    Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update

    SAN FRANCISCO, May 11, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2022 and provided corporate updates.

  • Business Wire

    Spruce Biosciences to Participate in May Investor Conferences

    SAN FRANCISCO, May 03, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in May.

  • Business Wire

    Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C., as Chief Regulatory and Quality Officer

    SAN FRANCISCO, April 11, 2022--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Libbie Mansell, Ph.D., M.B.A., R.A.C., has been appointed Chief Regulatory and Quality Officer. Dr. Mansell will be responsible for leading the company’s global regulatory affairs and quality strategy.